Pathophysiology of viral-induced exacerbations of COPD

International Journal of COPD

Volumn 2, Issue 4, 2007, Pages 477-483

  Alfredo, Potena ^a   Gaetano, Caramori ^b   Paolo, Casolari ^b   Marco, Contoli ^b   Johnston, Sebastian L ^c   Alberto, Papi ^b  

^a UNIVERSITY HOSPITAL OF FERRARA   (Italy)

^b UNIVERSITY OF FERRARA   (Italy)

^c NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIVIRUS AGENT; CELL ADHESION MOLECULE; CHEMOKINE; CYTOKINE; GROWTH FACTOR; PLACEBO; SIALIDASE INHIBITOR; TELITHROMYCIN; TRANSCRIPTION FACTOR;

AIRWAY OBSTRUCTION; BACTERIAL COLONIZATION; CELL SPECIFICITY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CIGARETTE SMOKING; CLINICAL TRIAL; CYTOKINE PRODUCTION; DISEASE EXACERBATION; DYSPNEA; EOSINOPHILIA; GENE EXPRESSION REGULATION; HIGH RISK PATIENT; HUMAN; HUMAN RHINOVIRUS; INFECTION SENSITIVITY; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY TRACT INFLAMMATION; RESPIRATORY VIRUS; REVIEW; SPUTUM ANALYSIS; TRANSCRIPTION REGULATION; VIRAL RESPIRATORY TRACT INFECTION; VIRUS VIRULENCE;

BRONCHITIS; GREAT BRITAIN; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY TRACT INFECTIONS;

EID: 38049141855     PISSN: 11769106     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (72)

1. Aaron SD, Angel JB, Lunau M, et al. 2001. Granulocyte inflammatory markers and airway infection during acute exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 163:349-55.
2. Alexopoulou L, Holt AC, Medzhitov R, et al. 2001. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature, 413:732-8.
3. Arnold R, Konig W. 2005. Respiratory syncytial virus infection of human lung endothelial cells enhances selectively intercellular adhesion molecule-1 expression. J Immunol, 174:7359-767.
4. Becker S, Soukup J, Yankaskas JR. 1992. Respiratory syncytial virus infection of human primary nasal and bronchial epithelial cell cultures and bronchoalveolar macrophages. Am J Respir Cell Mol Biol, 6:369-74.
5. Becker S, Soukup JM. 1999. Airway epithelial cell-induced activation of monocytes and eosinophils in respiratory syncytial viral infection. Immunobiology, 201:88-106.
6. Beckham JD, Cadena A, Lin J, et al. 2005. Respiratory viral infections in patients with chronic, obstructive pulmonary disease. J Infect, 322-30.
7. Behera AK, Matsuse H, Kumar M, et al. 2001. Blocking intercellular adhesion molecule-1 on human epithelial cells decreases respiratory syncytial virus infection. Biochem Biophys Res Commun, 280:188-95.
8. Caramori G, Ito K, Adcock IM. 2004. Transcription factors in asthma and COPD. IDrugs, 7:764-70.
9. Caramori G, Ito K, Contoli M, et al. 2006. Molecular mechanisms of respiratory virus-induced astfuna and COPD exacerbations and pneumonia. Curr Med Chem, 13:2267-90.
10. Casola A, Garofalo RP, Jamaluddin M, et al. 2000. Requirement of a novel upstream response element in respiratory syncytial virus-induced IL-8 gene expression. J Immunol, 164:5944-51.
11. Chen W, Monick MM, Carter AB, et al. 2000. Activation of ERK2 by respiratory syncytial virus in A549 cells is linked to the production of interleukin 8. Exp Lung Res, 26:13-26.
12. Chouldhary S, Boldogh S, Garofalo R, et al. 2005. Respiratory syncytial virus influences NF-kappaB-dependent gene expression through a novel pathway involving MAP3K14/NIK expression and nuclear complex formation with NF-kappaB2. J Virol, 79:8948-59.
13. Contoli M, Message SD, Laza-Stanca V, et al. 2006. Role of deficient type III interferon-lambda production in asthma exacerbations. Nat Med, 12:1023-6.
14. Cooper NJ, Sutton AJ, Abrams KR, et al. 2003. Effectiveness of neuraminidase inhibitors in treatment and prevention of influenza A and B: systematic review and meta-analyses of randomised controlled trials. BMJ, 326:1235.
15. de Graaff PM, de Jong EC, van Capel TM, et al. 2005. Respiratory syncytial virus infection of monocyte-derived dendritic cells decreases their capacity to activate CD4 T cells. J Immunol, 175:5904-11.
16. Donaldson GC, Seemungal TA, Bhowmik A, et al. 2002. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax, 57:847-52.
17. Falsey AR, Criddle MC, Walsh EE. 2006. Detection of respiratory syncytial virus and human metapneumovirus by reverse transcription polymerase chain reaction in adults with and without respiratory illness. J Clin Prol, 35:46-50.
18. Falsey AR, Hennessey PA, Formica MA, et al. 2005. Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med, 352:1749-59.
19. Falsey AR, Walsh EE. 2000. Respiratory syncytial virus infection in adults. Clin Microbiol Rev, 13:371-84.
20. Fiedler MA, Wernke-Dollries K, Stark JM. 1996. Inhibition of viral replication reverses respiratory syncytial virus-induced NF-kappaB activation and interleukin-8 gene expression in A549 cells. J Virol, 70:9079-82.
21. Fraenkel DJ, Bardin PG, Sanderson G, et al. 1995. Lower airways inflammation during rhinovirus colds in normal and in asthmatic subjects. Am J Respir Crit Care Med, 151:879-86.
22. Gern JE, Vrtis R, Grindle KA, et al. 2000. Relationship of upper and lower airway cytokines to outcome of experimental rhinovirus infection. Am J Respir Crit Care Med, 162:2226-31.
23. [GOLD] Global Initiative for Chronic Obstructive Lung Disease, National Institute of Health, National Heart Lung, and Blood Institute. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Workshop report. NIH Publication No 2701 A, March 2001. Update 2006.
24. Greve JM, Davis G, Meyer AM, et al. 1989. The major human rhinovirus receptor is ICAM-1. Cell, 56:839-47.
25. Guerrero-Plata A, Casola A, Suarez G, et al. 2006. Differential response of dendritic cells to human metapneumovirus and respiratory syncytial virus. Am J Respir Cell Mol Biol, 34:320-9.
26. Hall CB. 2000. Nosocomial respiratory syncytial virus infections: the "Cold War" has not ended. Clin Infect Dis, 31:590-6.
27. Hall CB. 2001. Respiratory syncytial virus and parainfluenza virus. N Engl J Med, 344:1917-28.
28. Hamelin ME, Cote S, Laforge J, et al. 2005. Human metapneumovirus infection in adults with community-acquired pneumonia and exacerbation of chronic obstructive pulmonary disease. Clin Infect Dis, 41:498-502.
29. Hofer F, Gruenberger M, Kowalski H, et al. 1994. Members of the low density lipoprotein receptor family mediate cell entry of a minor-group common cold virus. Proc Natl Acad Sci USA, 91:1839-42.
30. Hurst JR, Donaldson GC, Wilkinson TM, et al. 2005. Epidemiological relationships between the common cold and exacerbation frequency in COPD. Eur Respir J, 26:846-52.
31. Jamaluddin M, Casola A, Garofalo RP, et al. 1998, The major component of IkB proteolysis occurs independently of the proteasome pathway in respiratory syncytial virus-infected pulmonary epithelial cells. J Virol, 72:4849-57.
32. Johnston SL. 2005. Overview of virus-induced airway disease. Proc Am Thorac Soc, 2:150-6.
33. Johnston SL, Blasi F, Black PN, et al. 2006. The effect of telithromycin in acute exacerbations of asthma. N Engl J Med, 354:1589-600.
34. Kaiser L, Wat C, Mills T, et al. 2003. Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations. Arch Intern Med, 163:1667-72.
35. Koga T, Sardina E, Tidwell RM, et al. 1999. Virus-inducible expression of a host chemokine gene relies on replication-linked mRNA stabilization. Proc Natl Acad Sci USA, 96:5680-5.
36. Kong X, San Juan H, Behera A, et al. 2004. ERK-1/2 activity is required for efficient RSV infection. FEBS Lett, 559:33-8.
37. Lalezari J, Campion K, Keene O, et al. 2001. Zanamivir for the treatment of influenza A and B infection in high-risk patients: a pooled analysis of randomized controlled trials. Arch Intern Med, 161:212-17.
38. Mallia P, Contoli M, Caramori G, et al. 2007. Exacerbations of asthma and chronic obstructive pulmonary disease (COPD). Focus on virus induced exacerbations. Curr Pharm Des, 13:73-97.
39. Mallia P, Message SD, Kebadze T, et al. 2006. An experimental model of rhinovirus induced chronic obstructive pulmonary disease exacerbations: a pilot study. Respir Res, 7:116.
40. Mastronarde JG, Monick MM, Mukaida N, et al. 1998. Activator protein-1 is the preferred transcription factor for cooperative interaction with nuclear factor-κB in respiratory syncytial virus-induced interleukin-8 gene expression in airway epithelium. J Infect Dis, 177:1275-81.
41. Myatt TA, Johnston SL, Rudnick S, et al. 2003. Airborne rhinovirus detection and effect of ultraviolet irradiation on detection by a semi-nested RT-PCR assay. BMC Public Health, 3:5.
42. Oliveira MA, Zhao R, Lee WM, et al. 1993. The structure of human rhinovirus 16. Structure, 1:51-68.
43. Papadopoulos NG, Stanciu LA, Papi A, et al. 2002. A defective type 1 response to rhinovirus in atopic asthma. Thorax, 57:328-32.
44. Papi A, Bellettato CM, Braccioni F, et al. 2006. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am J Respir Crit Care Med, 173:1114-21.
45. Papi A, Johnston SL. 1999a. Respiratory epithelial cell expression of vascular cell adhesion molecule-1 and its up-regulation by rhinovirus infection via NF-kappaB and GATA transcription factors. J Biol Chem, 274:30041-51.
46. Papi A, Johnston SL. 1999b. Rhinovirus infection induces expression of its own receptor intercellular adhesion molecule 1 (ICAM-1) via increased NF-kappaB-mediated transcription. J Biol Chem, 274:9707-20.
47. Papi A, Papadopoulos NG, Stanciu LA, et al. 2002. Reducing agents inhibit rhinovirus-induced up-regulation of the rhinovirus receptor intercellular adhesion molecule-1 (ICAM-1) in respiratory epithelial cells. Faseb J, 16:1934-6.
48. Patel IS, Seemungal TA, Wilks M, et al. 2002. Relationship between bacterial colonisation and the frequency, character, and severity of COPD exacerbations. Thorax, 57:759-64.
49. Qiu Y, Zhu J, Bandi V, et al. 2003. Biopsy neutrophilia, neutrophil chemokine and receptor gene expression in severe exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 168:968-75.
50. Ram FS, Rodriguez-Roisin R, Granados-Navarrete A, et al. 2006. Antibiotics for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev, 19:CD004403.
51. Reimers K, Buchholz K, Werchau H. 2005, Respiratory syncytial virus M2-1 protein induces the activation of nuclear factor kappa B. Virology, 331:260-8.
52. Retamales I, Elliott WM, Meshi B, et al. 2001. Amplification of inflammation in emphysema and its association with latent adenoviral infection. Am J Respir Crit Care Med, 164:469-73.
53. Rixon HW, Brown G, Murray JT, et al. 2005. The respiratory syncytial virus small hydrophobic protein is phosphorylated via a mitogen-activated protein kinase p38-dependent tyrosine kinase activity during virus infection. J Gen Virol, 86:375-84.
54. Robbins CS, Dawe DE, Goncharova SI, et al. 2004. Cigarette smoke decreases pulmonary dendritic cells and impacts antiviral immune responsiveness. Am J Respir Cell Mol Biol, 30:202-11.
55. Rohde G, Wiethege A, Borg I, et al. 2003. Respiratory viruses in exacerbations of chronic obstructive pulmonary disease requiring hospitalisation: a case-control study. Thorax, 58:37-42.
56. Sajjan US, Jia Y, Newcomb DC, et al. 2006. H. influenzae potentiates airway epithelial cell responses to rhinovirus by increasing ICAM-1 and TLR3 expression. FASEB J, 20:2121-3.
57. Samet JM. 2004. How do we catch colds? Am J Respir Crit Care Med, 169:1175-6.
58. Seemungal T, Harper-Owen R, Bhowmik A, et al. 2001. Respiratory viruses, symptoms, and inflammatory markers in acute exacerbations and stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 164:1618-23.
59. Seemungal TA, Donaldson GC, Bhowmik A, et al. 2000. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 161:1608-13.
60. Seemungal TA, Donaldson GC, Paul EA, et al. 1998. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 157:1418-22.
61. Sethi S, Murphy TF. 2001. Bacterial infection in chronic obstructive pulmonary disease in 2000: a state-of-the-art review. Clin Microbiol Rev, 14:336-63.
62. Sethi S, Murphy TF. 2005. RSV infection - not for kids only. N Engl J Med, 352:1810-2.
63. Spann KM, Tran KC, Collins PL. 2005. Effects of nonstructural proteins NS1 and NS2 of human respiratory syncytial virus on interferon regulatory factor 3, NF-kappaB, and proinflammatory cytokines. J Virol, 79:5353-62.
64. Sullivan SD, Ramsey SD, Lee TA. 2000. The economic burden of COPD. Chest, 117 (2 Suppl):5S-9S.
65. Terajima M, Yamaya M, Sekizawa K, et al. 1997. Rhinovirus infection of primary cultures of human tracheal epithelium: role of ICAM-1 and IL-1beta. Am J Physiol, 273:L749-59.
66. Walsh EE, Falsey AR. 2004. Age related differences in humoral immune response to respiratory syncytial virus infection in adults. J Med Virol, 73:295-9.
67. Wark P, Johnston SL, Bucchieri F, et al. 2005. Asthmatic bronchial epithelial cells have a deficient innate immune response to infection with rhinovirus. J Exp Med, 201:937-47.
68. Wedzicha JA. 2004. Role of viruses in exacerbations of chronic obstructive pulmonary disease. Proc Am Thorac Soc, 1:115-20.
69. Wedzicha JA, Donaldson GC. 2003. Exacerbations of chronic obstructive pulmonary disease. Respir Care, 48:1204-13.
70. White AJ, Gompertz S, Stockley RA. 2003. Chronic obstructive pulmonary disease. 6: The actiology of exacerbations of chronic obstructive pulmonary disease. Thorax, 58:73-80.
71. Wilkinson TM, Hurst JR, Perera WR, et al. 2006. Effect of interactions between lower airway bacterial and rhinoviral infection in exacerbations of COPD. Chest, 129:317-24.
72. Zhu J, Qiu YS, Majumdar S, et al. 2001. Exacerbations of Bronchitis: bronchial eosinophilia and gene expression for interleukin-4, interleukin-5 and eosinophil chemoattractants. Am J Respir Crit Care Med, 164:109-16.